Comparing the visual analogue scale and the numerical rating scale in patient-reported outcomes in psoriatic arthritis by Ye, W, Hackett, S, Vandevelde, C, Twigg, S, Helliwell, PS, Coates, LC

Measuring physical function in psoriatic arthritis: comparing the Multi-Dimensional Health Assessment Questionnaire to the Health Assessment Questionnaire Disability Index by Ye, W, Hackett, S, Vandevelde, C, Twigg, S, Helliwell, PS, Coates, LC

Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores by Weinstein, SM, Coates, LC, Helliwell, PS, Ogdie, A, Stephens-Shields, AJ

Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial by Coates, L, Mahmood, F, Freeston, J, Emery, P, Conaghan, PG, Helliwell, PS

What should be the primary target of "treat to target" in psoriatic arthritis? by Coates, LC, Lubrano, E, Perrotta, FM, Emery, P, Conaghan, PG, Helliwell, PS

Quality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment by Coates, LC, Birt, J, Kronbergs, A, Bolce, R, Bradley, AJ, Park, SY, Helliwell, PS

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo by Gladman, DD, Coates, LC, Wu, J, Fallon, L, Bacci, ED, Cappelleri, JC, Bushmakin, AG, Helliwell, PS

The comparative performance of three screening questionnaires for psoriatic arthritis in a primary care surveillance study by Helliwell, PS, Coates, LC, Ransom, M, Brown, ST, Packham, J, Weddell, J, Tillett, W, McHugh, N

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib by Coates, L, Bushmakin, AG, FitzGerald, O, Gladman, DD, Fallon, L, Cappelleri, JC, Hsu, MA, Helliwell, PS

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire by Helliwell, PS, Tillett, W, Waxman, R, Coates, LC, Brooke, M, FitzGerald, O, Packham, JC, McHugh, N

GRAPPA 2018 project report by Goel, N, Fitzgerald, O, Gladman, DD, Helliwell, PS, Kavanaugh, A, Maksymowych, WP, Mease, PJ, Ritchlin, CT, Coates, LC

Screening/referral strategies for the early recognition of psoriatic arthritis (PsA) among patients with psoriasis: results of a GRAPPA survey by Song, K, Eder, L, FitzGerald, O, Goel, N, Helliwell, PS, Katz, A, Merola, JF, Rosen, CF, Coates, L, Poddubnyy, D

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial by Helliwell, PS, Mease, PJ, Kavanaugh, A, Coates, LC, Ogdie, A, Deodhar, A, Strand, V, Kricorian, G, Liu, L, Collier, D, Gladman, DD

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis by Coates, LC, Smolen, JS, Mease, PJ, Husni, ME, Merola, JF, Lespessailles, E, Kishimoto, M, Macpherson, L, Bradley, AJ, Bolce, R, Helliwell, PS

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study by Coates, LC, Gossec, L, Zimmermann, M, Shawi, M, Rampakakis, E, Shiff, NJ, Kollmeier, AP, Xu, XL, Nash, P, Mease, PJ, Helliwell, PS

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis by Yazji, SM, Helliwell, PS, Balanescu, A, Dernis, E, Kiltz, U, Kalyoncu, U, Leung, YY, Orbai, A-M, Smolen, JS, de Wit, M, Gossec, L, Coates, LC

Meaningful improvement in general health outcomes with Guselkumab treatment for psoriatic arthritis: Patient-Reported Outcomes Measurement Information System-29 results from a phas... by Orbai, A-M, Coates, LC, Deodhar, A, Helliwell, PS, Ritchlin, CT, Leibowitz, E, Kollmeier, AP, Hsia, EC, Xu, XL, Sheng, S, Jiang, Y, Liu, Y, Han, C

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis by Coates, L, Ritchlin, CT, Gossec, L, Helliwell, PS, Rahman, P, Kollmeier, AP, Xu, XL, Shawi, M, Karyekar, CS, Contré, C, Noël, W, Sheng, S, Wang, Y, Xu, S, Mease, PJ

Outcomes of the 2019 GRAPPA workshop on continuous composite indices for the assessment of psoriatic arthritis and membership: Recommended next steps by Tillett, W, McHugh, N, Orbai, AM, Ogdie, A, Leung, YY, Coates, LC, Mease, P, Gladman, DD, Brooke, M, Packham, J, O’Sullivan, D, FitzGerald, O, Helliwell, PS

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis by Coates, L, Merola, JF, Mease, PJ, Ogdie, A, Gladman, DD, Strand, V, van Mens, L J.J., Liu, L, Yen, PK, Collier, DH, Kricorian, G, Chung, JB, Helliwell, PS